'Repurposed' anti-parasite drug shows promise as new TB treatment

November 23, 2012

(Medical Xpress)—A well-established family of drugs used to treat parasitic diseases is showing surprising potential as a therapy for tuberculosis (TB), according to new research from University of British Columbia microbiologists.

The findings, published online this week in the journal , are based on in vitro tests of the avermectin family of drugs. Discovered nearly 40 years ago, the drugs are commonly used in the developing world to eliminate the that cause and elephantiasis but have been thought to be ineffective against . The UBC study shows that in the lab, the drugs actually killed the bacteria that cause TB, including drug resistant forms.

"These drugs are cheap, routinely produced by pharmaceutical companies, and, in many cases, approved for humans use," says UBC researcher Santiago Ramón-García, a co-author on the paper. "So the jump from lab bench to clinic could be much quicker."

"In addition, the drug concentrations effective in vitro indicate members of this family might be very valuable additions to the small repertoire of drugs we have to fight multi-, which have very low probabilities of being cured."

The international collaboration was lead by scientists in UBC's Department of Microbiology and Immunology associated with UBC's Centre for Tuberculosis Research and the Neglected Global Diseases Initiative.

"This underscores the great potential for investments in research to find new uses for approved drugs or synergistic drug combinations," says co-author and UBC microbiologist Charles Thompson.

Further studies are needed to assess the drugs' clinical application for treating TB. UBC researchers are now working with animal models to determine effective dosage levels and regimens. They will also study whether avermectins could be combined with other drugs to create effective therapies.

Explore further: NIAID describes research priorities to fight drug-resistant tuberculosis

Related Stories

Drug-resistant tuberculosis rife in China

December 11, 2008

Levels of drug-resistant tuberculosis (TB) in China are nearly twice the global average. Nationwide research published in the open access journal BMC Infectious Diseases has shown that almost 10% of Chinese TB cases are resistant ...

Drug-resistant TB blamed on Indian treatment flaws

March 23, 2012

(AP) -- India's inadequate government-run tuberculosis treatment programs and a lack of regulation of the sale of drugs that fight it are responsible for the spiraling number of drug-resistant cases that are difficult to ...

Recommended for you

Immune breakthrough: Unscratching poison ivy's rash

August 23, 2016

We all know that a brush with poison ivy leaves us with an itchy painful rash. Now, Monash University and Harvard researchers have discovered the molecular cause of this irritation. The finding brings us a step closer to ...

Zika infection may affect adult brain cells

August 18, 2016

Concerns over the Zika virus have focused on pregnant women due to mounting evidence that it causes brain abnormalities in developing fetuses. However, new research in mice from scientists at The Rockefeller University and ...

Monkeys with Sudan ebolavirus treated successfully

August 22, 2016

Scientists funded by the National Institutes of Health (NIH) have successfully treated monkeys several days after the animals were infected with Sudan ebolavirus (SUDV). The study is important, according to the researchers, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.